Furthermore, Ito et al. found that increasing access to preventive medications, including β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins and aspirin, to post-myocardial infarction patients improves health outcomes and also decreases healthcare spending over the long-term [12]. The gene discussed is ACE; the disease is myocardial infarction.